Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
McKinsey
Boehringer Ingelheim
Harvard Business School
Moodys

Last Updated: October 1, 2022

Details for Patent: 8,865,688


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 8,865,688 protect, and when does it expire?

Patent 8,865,688 protects APRISO and is included in one NDA.

This patent has sixteen patent family members in thirteen countries.

Summary for Patent: 8,865,688
Title:Compositions and methods for treatment of bowel diseases with granulated mesalamine
Abstract: Disclosed are methods for treating gastrointestinal disorders, e.g., Crohn's disease, ulcerative colitis, and diverticular disease, with a granulated mesalamine formulation. Some formulations use granulated mesalamine in capsule form. Also included are methods to extend remission of ulcerative colitis by administration of a once-daily dosage of granulated mesalamine.
Inventor(s): Forbes; William (Raleigh, NC)
Assignee: Dr. Falk Pharma GmbH (DE)
Application Number:12/573,081
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,865,688
Patent Claim Types:
see list of patent claims
Use; Formulation; Dosage form;

Drugs Protected by US Patent 8,865,688

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Valeant Pharms Intl APRISO mesalamine CAPSULE, EXTENDED RELEASE;ORAL 022301-001 Oct 31, 2008 AB RX Yes Yes See Plans and Pricing See Plans and Pricing FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,865,688

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2009298139 See Plans and Pricing
Canada 2739465 See Plans and Pricing
Chile 2011000744 See Plans and Pricing
China 102238868 See Plans and Pricing
Eurasian Patent Organization 022886 See Plans and Pricing
Eurasian Patent Organization 201100565 See Plans and Pricing
European Patent Office 2334178 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
McKesson
Mallinckrodt
Colorcon
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.